Endogenous ADAR-Mediated RNA Editing Therapeutics
FREST develops guide RNA-based therapeutics that recruit endogenous ADAR to edit disease-relevant mRNA without permanent genome modification
Technology snapshot
Why RNA editing / Platform value
RNA editing enables transient and reversible modulation of genetic information at the RNA level. By leveraging endogenous ADAR, FREST aims to develop therapeutics without introducing exogenous editing enzymes.
Partnering to advance RNA editing therapeutics.
FREST is developing endogenous ADAR-mediated RNA-editing therapeutics for genetically defined diseases. We aim to expand the therapeutic potential of our platform through partnerships with pharmaceutical companies, academic researchers, and healthcare innovators.
We welcome discussions with pharmaceutical partners on target selection, guide RNA design, delivery optimization, in vivo proof-of-concept, and disease-area expansion.